In vitro genotoxicity assessment of graphene quantum dots nanoparticles: A metabolism-dependent response

Abstract

Nanomaterials are progressively being applied in different areas, including biomedical uses. Carbon nanomaterials are relevant for biomedical sciences because of their biocompatibility properties. Graphene quantum dots (GQD) have a substantial potential in drug-delivery nanostructured biosystems, but there is still a lack of toxicological information regarding their effects on human health and the environment. We thus evaluated the mutagenicity, cytotoxicity and genotoxicity of this nanomaterial using alternative methods applied in regulatory toxicology guidelines. The Ames test was carried out in the presence and absence of exogenous metabolization. Salmonella enterica serovar Typhimurium strains TA97a, TA98, TA100, TA102, TA104, and TA1535 were exposed to GQD with concentrations ranging from 1 to 1000 μg/plate. The mammal cell viability assays were carried out with HepG2 and 3T3BalbC cell lineages and the in vitro Cytokinesis-Block Micronucleus assay (CBMN) was applied for 24 h of exposure in non-cytotoxic concentrations. Mutagenicity was induced in the TA97a strain in the absence of exogenous metabolization, but not in its presence. Mutagenicity was also detected in the TA102 strain in the assay with exogenous metabolization, suggesting redox misbalance mutagenicity. The WST-1 and LDH assays demonstrated that GQD decreased cell viability, especially in 3T3BalbC cells, which showed more sensitivity to the nanomaterial. GQD also increased micronuclei formation in 3T3BalbC and caused a cytostatic effect. No significant impact on HepG2 micronuclei formation was observed. Different metabolic systems interfered with the mutagenic, cytotoxic, and genotoxic effects of GQD, indicating that liver metabolism has a central role in the detoxification of this nanomaterial.